Ileus News and Research

RSS
Ileus or gastrointestinal atony is a disruption of the normal propulsive gastrointestinal motor activity due to non-mechanical causes.
J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study

The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi launches CUVPOSA for pediatric chronic severe drooling

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Mallinckrodt receives FDA approval for Fentanyl Transdermal System patch ANDA

Mallinckrodt receives FDA approval for Fentanyl Transdermal System patch ANDA

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna receives approval for chronic myeloid leukemia in Canada

Endo to acquire Penwest for $5.00 per share

Endo to acquire Penwest for $5.00 per share

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients